Becton, Dickinson and Company

NYSE:BDX Stok Raporu

Piyasa değeri: US$42.6b

Becton Dickinson Yönetim

Yönetim kriter kontrolleri 4/4

Becton Dickinson CEO'su Tom Polen, Apr2017 tarihinde atandı, in görev süresi 6.25 yıldır. in toplam yıllık tazminatı $ 17.13M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.1% maaş ve 91.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.036% ine doğrudan sahiptir ve bu hisseler $ 15.15M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.6 yıl ve 7 yıldır.

Anahtar bilgiler

Tom Polen

İcra Kurulu Başkanı

US$17.1m

Toplam tazminat

CEO maaş yüzdesi8.15%
CEO görev süresi9yrs
CEO sahipliği0.04%
Yönetim ortalama görev süresi3.6yrs
Yönetim Kurulu ortalama görev süresi7yrs

Son yönetim güncellemeleri

Recent updates

Becton, Dickinson: Value Or Overvalued Even Now?

Apr 20

BDX: 2026 MedTech Setup And Buybacks Will Support Upside Potential

Analyst price targets for Becton Dickinson have edged lower, with the fair value estimate moving from about $196.08 to $192.31 as analysts factor in slightly higher discount rates, modestly softer revenue growth and profit margins, and a somewhat higher future P/E multiple. Analyst Commentary Recent Street research on Becton Dickinson reflects a mix of optimism and caution, with several firms adjusting price targets and ratings as they reassess execution risks and valuation assumptions.

BDX: 2026 MedTech Setup And Tuck In M&A Will Support Upside

Analysts have trimmed their average price target for Becton Dickinson by about $1, reflecting slightly lower fair value and P/E assumptions, along with modestly higher profit margin expectations. Analyst Commentary Recent Street research on Becton Dickinson has featured several price target changes and rating actions that point to a mix of optimism about execution and caution around valuation and growth assumptions.

BDX: 2026 MedTech Setup And Tuck In M&A Will Drive Upside

Narrative Update The latest analyst work on Becton Dickinson points to a mixed shift in price targets, with some firms raising their views by $12.30 to $15.00 while others trimmed estimates by $1.00 to $38.00, as analysts reassessed near term pressures, longer term MedTech prospects into 2026, and valuation assumptions including discount rate and future P/E inputs. Analyst Commentary Recent Street research on Becton Dickinson points to a split view, with some analysts lifting targets and others trimming them as they rework models for 2025 pressures and the setup into 2026.

BDX: 2026 MedTech Setup And Buybacks Will Shape Upside Potential

The analyst price target for Becton Dickinson has been adjusted to approximately $197 from about $195, as analysts factor in recently updated views on large cap MedTech setups, leading to slightly higher fair value and P/E assumptions. Analyst Commentary Recent research on Becton Dickinson reflects a mix of optimism and caution, with several firms adjusting price targets and ratings as they reassess large cap MedTech names and Becton Dickinson's role within that group.

BDX: 2026 Reset With Mixed Research And Product Pipeline Will Shape Returns

Analysts have trimmed their average price target on Becton Dickinson by about $9 to reflect more cautious assumptions on revenue growth and margins. This is partly offset by a willingness to apply a higher future P/E multiple as recent research updates reset expectations across the sector.

BDX: FY26 Guidance Reset Will Support More Constructive 2026 MedTech Setup

Narrative update The analyst price target for Becton Dickinson has been revised from about US$322 to about US$253. Analysts cite updated assumptions for growth, margins and future P/E, and they also reflect mixed recent Street research that includes both target raises and cuts following FY26 guidance and Q4 results.

Becton Dickinson (NYSE:BDX) Will Pay A Dividend Of $1.05

Jan 31
Becton Dickinson (NYSE:BDX) Will Pay A Dividend Of $1.05

BDX: FY26 Reset And Alaris China And Vaccine Headwinds Will Pressure Outlook

Analysts have modestly adjusted their price expectations for Becton Dickinson, with recent Street targets ranging from a reduction to $202 to an increase to $215. They are balancing near term headwinds in areas like Alaris, China, and vaccines against what some see as a more constructive setup heading into 2026 for large cap MedTech.

BDX: 2026 Reset And Headwinds Will Shape Fairly Balanced Return Potential

Analysts have modestly adjusted their fair value estimate for Becton Dickinson to about $205 per share, reflecting updated views on slower profit margin assumptions, a somewhat higher future P/E, and recent price target resets around $202 to $210 following Q4 results and FY26 guidance. Analyst Commentary Recent Street research has focused on how Becton Dickinson's latest Q4 results and FY26 outlook feed into valuation, execution risk, and growth expectations.

BDX: FY26 Reset And Business Separation Will Shape Balanced Risk Reward Outlook

We raise our fair value estimate for Becton Dickinson to $183 from $172 per share, reflecting analysts' view that a conservative FY26 reset, modestly higher long term profitability, and a slightly richer future earnings multiple more than offset near term revenue growth headwinds and higher risk premia embedded in the discount rate. Analyst Commentary Bearish analysts are converging around a more cautious outlook for Becton Dickinson, trimming price targets and highlighting execution risks that could cap near term upside.

BDX: 2026 Separation And Reset Outlook Will Shape Returns Amid Headwinds

Analysts have modestly lowered their price target on Becton Dickinson to about $203 per share from roughly $201 previously. This reflects slightly higher long term revenue growth assumptions, offset by a marginally lower profit margin outlook and cautious views on FY26 guidance amid Alaris, China, and vaccine related headwinds.

Becton Dickinson's (NYSE:BDX) Dividend Will Be Increased To $1.05

Nov 24
Becton Dickinson's (NYSE:BDX) Dividend Will Be Increased To $1.05

BDX: Modest Guidance and 2026 Separation Will Shape Future Performance Amid Headwinds

Becton Dickinson's analyst price target was reduced from approximately $206.58 to $201.49. Analysts attribute this change to cautious forward guidance, modest revenue expectations, and ongoing external headwinds highlighted in recent reports.

Some Investors May Be Willing To Look Past Becton Dickinson's (NYSE:BDX) Soft Earnings

Nov 16
Some Investors May Be Willing To Look Past Becton Dickinson's (NYSE:BDX) Soft Earnings

Becton Dickinson (NYSE:BDX) Has Announced That It Will Be Increasing Its Dividend To $1.05

Nov 09
Becton Dickinson (NYSE:BDX) Has Announced That It Will Be Increasing Its Dividend To $1.05

BDX Will Unlock New Growth Following Planned 2026 Business Separation

Becton Dickinson Analyst Price Target Narrative Update The analyst fair value estimate for Becton Dickinson was reduced slightly from $208 to approximately $206.58, with analysts citing a more conservative earnings outlook and limited growth expectations in the near term. Analyst Commentary Analyst perspectives on Becton Dickinson reflect a balanced view of the company’s near-term challenges and long-term opportunities.

Becton, Dickinson and Company: It's Wait And See For Me

Apr 27

Becton Dickinson Could Be Cure To Demand For Medtech Supplies, With Robust Pipeline

Mar 30

Beckton, Dickinson: Hold, Momentum Is Gaining, Just Need More Growth

Jan 20

CEO Tazminat Analizi

Tom Polen'un ücretlendirmesi Becton Dickinson'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Dec 31 2025n/an/a

US$2b

Sep 30 2025US$17mUS$1m

US$2b

Jun 30 2025n/an/a

US$2b

Mar 31 2025n/an/a

US$1b

Dec 31 2024n/an/a

US$2b

Sep 30 2024US$17mUS$1m

US$2b

Jun 30 2024n/an/a

US$1b

Mar 31 2024n/an/a

US$1b

Dec 31 2023n/an/a

US$1b

Sep 30 2023US$17mUS$1m

US$1b

Jun 30 2023n/an/a

US$2b

Mar 31 2023n/an/a

US$2b

Dec 31 2022n/an/a

US$1b

Sep 30 2022US$17mUS$1m

US$2b

Jun 30 2022n/an/a

US$1b

Mar 31 2022n/an/a

US$1b

Dec 31 2021n/an/a

US$1b

Sep 30 2021US$14mUS$1m

US$2b

Jun 30 2021n/an/a

US$1b

Mar 31 2021n/an/a

US$1b

Dec 31 2020n/an/a

US$2b

Sep 30 2020US$12mUS$952k

US$245m

Jun 30 2020n/an/a

US$786m

Mar 31 2020n/an/a

US$923m

Dec 31 2019n/an/a

US$760m

Sep 30 2019US$6mUS$900k

US$1b

Tazminat ve Piyasa: Tom 'ın toplam tazminatı ($USD 17.13M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 14.50M ).

Tazminat ve Kazançlar: Tom 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Tom Polen (52 yo)

9yrs
Görev süresi
US$17,129,139
Tazminat

Mr. Thomas E. Polen, Jr., also known as Tom, serves as Chief Executive Officer and Director at Becton, Dickinson and Company since January 28, 2020. Mr. Polen served as an Independent Director at Walgreens...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Thomas Polen
President9yrsUS$17.13m0.036%
$ 15.1m
Michael Garrison
Executive VP & President of Medical Segment and BioPharma Systems Segments3.6yrsUS$3.65m0.0043%
$ 1.8m
Richard Byrd
Executive VP & President of Interventional Segment3.6yrsUS$3.40m0.0011%
$ 489.6k
Michael Feld
Executive VP & Chief Revenue Officerless than a yearUS$4.10m0.0075%
$ 3.2m
Vitor Roque
Senior VP of Business Finance & Interim CFOless than a yearVeri yok0.0023%
$ 975.0k
Pamela Spikner
Senior VP1.3yrsVeri yok0.0012%
$ 498.1k
Elizabeth McCombs
Executive VP & CTO5yrsVeri yokVeri yok
Joseph Smith
Senior VP & Chief Scientific Officer4.4yrsVeri yokVeri yok
Denise Fleming
Executive VP of Technology & Global Services and Chief Information Officer4.3yrsVeri yokVeri yok
Shawn Bevec
Senior Vice President of Investor Relationsless than a yearVeri yokVeri yok
Claudia Curtis
Senior VPno dataVeri yokVeri yok
Lanesha Minnix
Executive VP & General Counselless than a yearVeri yokVeri yok
3.6yrs
Ortalama Görev Süresi
49yo
Ortalama Yaş

Deneyimli Yönetim: BDX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.6 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Thomas Polen
President6.3yrsUS$17.13m0.036%
$ 15.1m
Robert Eckert
Lead Independent Director9.6yrsUS$365.17k0.0037%
$ 1.6m
Timothy Ring
Independent Director9.3yrsUS$335.17k0.022%
$ 9.2m
Jeffrey Henderson
Independent Director7.7yrsUS$360.17k0.0032%
$ 1.4m
Christopher Ian Jones
Independent Director15.8yrsUS$365.17k0.0085%
$ 3.6m
Bertram Scott
Independent Director23.6yrsUS$375.17k0.013%
$ 5.5m
Gregory Hayes
Independent Director1.1yrsUS$223.45k0.0019%
$ 787.6k
Catherine Burzik
Independent Director13.3yrsUS$360.17k0.0033%
$ 1.4m
William Brown
Independent Director4.2yrsUS$335.17k0.0016%
$ 698.2k
Robert Huffines
Independent Directorless than a yearVeri yok0%
$ 0
Carrie Byington
Independent Director4.5yrsUS$345.17k0.0018%
$ 749.3k
Joanne Waldstreicher
Independent Director2.8yrsUS$336.17k0.00048%
$ 204.4k
7.0yrs
Ortalama Görev Süresi
63.5yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: BDX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/04/29 13:07
Gün Sonu Hisse Fiyatı2026/04/29 00:00
Kazançlar2025/12/31
Yıllık Kazançlar2025/09/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Becton, Dickinson and Company 35 Bu analistlerden 12, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
David ToungArgus Research Company
Adam FeinsteinBarclays
Matthew MiksicBarclays